Form 4: Merit Medical Chairman Sells 25,000 Shares

Merit Medical Systems Inc.'s Executive Chairman, Fred P. Lampropoulos, reported the sale of 25,000 shares of common stock at a weighted average price of $87.31.

Summary

• Fred P. Lampropoulos, Executive Chairman and Director of Merit Medical Systems Inc., sold 25,000 shares of common stock.
• The shares were sold on November 21, 2025, at a weighted average price of $87.31 per share, with individual transaction prices ranging from $87.0000 to $87.6708.
• The transaction was executed pursuant to a Rule 10b5-1(c) plan, indicating a pre-scheduled sale.
• Following the sale, Lampropoulos directly beneficially owns 1,029,955 shares of common stock.
• Indirect holdings include 8,280.258 shares held by his spouse, 98,132 shares in a 401(k) plan (as of October 31, 2025), and 90 shares held by his spouse as custodian for a child; beneficial ownership for spouse and child holdings is expressly disclaimed.
• Lampropoulos also holds non-qualified stock options to purchase 100,334 shares at an exercise price of $37.71, 58,083 shares at $56.25, and 54,302 shares at $70.58.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While an insider sale reduces direct ownership, it was executed under a pre-arranged 10b5-1 plan, which mitigates negative interpretations. The executive retains substantial holdings, indicating continued alignment with shareholder interests.

Positives

• The sale was conducted under a Rule 10b5-1(c) plan, indicating a pre-scheduled transaction rather than an immediate reaction to new, undisclosed information.
• Fred P. Lampropoulos retains a significant direct beneficial ownership of 1,029,955 shares, demonstrating continued alignment with shareholder interests.
• The sale price of $87.31 per share is at a relatively high valuation, suggesting the executive is realizing value at a favorable market price.

Negatives

• An insider sale, even under a 10b5-1 plan, can sometimes be perceived by the market as a signal that the stock may be fully valued or that the insider is reducing exposure.
• The reduction in direct beneficial ownership, while still substantial, decreases the executive's direct equity stake in the company.

Future Outlook

No future outlook or guidance is provided in this Form 4 filing.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends.

Corporate Governance

Related Party Transactions

• The sale of 25,000 shares of common stock by Fred P. Lampropoulos, an Executive Chairman and Director, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a signal, though the 10b5-1 plan mitigates concerns. The executive still holds a significant stake, maintaining alignment.
• Employees: No direct impact on employees is indicated by this transaction.
• Customers: No direct impact on customers is indicated by this transaction.
• Suppliers: No direct impact on suppliers is indicated by this transaction.
• Creditors: No direct impact on creditors is indicated by this transaction.

Key Dates

Recommendation

The insider sale by the Executive Chairman, while a reduction in direct holdings, was executed under a pre-arranged 10b5-1 plan, which suggests it is not based on new, undisclosed negative information. The executive retains a substantial number of shares and options, indicating continued vested interest in the company's performance. This transaction alone does not provide sufficient new information to warrant a change from a 'hold' position, as it appears to be a routine liquidity event.

Keywords

Merit Medical Systems, MMSI, Insider Sale, Form 4, Fred P. Lampropoulos, Executive Chairman, Stock Transaction, Equity Sales, 10b5-1 Plan, Beneficial Ownership